immunotherapy

Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors

Dr. Roger Dansey Dr. Roger Dansey joins Ottimo Pharma Limited Board of Directors Dansey, a former senior executive at Pfizer…

10 months ago

Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor

SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing…

10 months ago

BriaCell’s Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3

BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpointHighly expressed on the cell surfaces of…

10 months ago

Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, April 10, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the…

10 months ago

ValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEO

HELSINKI and NAPLES, Italy, April 09, 2025 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), an immunotherapy company developing novel, adaptable…

10 months ago

Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs

WARREN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a healthcare company…

10 months ago

Quibim Announces New Board of Directors To Promote Growth And Strategic Expansion

NEW YORK & VALENCIA, Spain & CAMBRIDGE, England--(BUSINESS WIRE)--#AIinHealthcare--Quibim, the global pioneer in imaging biomarkers for precision medicine, is pleased…

10 months ago

Global Cancer Research Community Gathers to Share Breakthroughs at The Mark Foundation’s 2025 Scientific Symposium

NEW YORK, April 3, 2025 /PRNewswire/ -- The Mark Foundation for Cancer Research convened more than 150 scientists from 13 states…

10 months ago

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to…

10 months ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…

10 months ago